000			04344nam a2200481 i 4500
999			_c382802 _d382802
001			382802
003			ES-MaUEC
005			20230102122017.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			220519s2022 sz | o |||| 0|eng d
020			_a9783030887193
024	7		_a10.1007/978-3-030-88719-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM301.25 _b2022 EB
245	0	0	_aFormulating Poorly Water Soluble Drugs _cedited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller
250			_a3rd edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XII, 693 páginas) _b280 ilustraciones, 138 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-738X _v50
505	0		_aRoute-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.
520			_aThe objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9161127 _aTecnología farmacéutica
650		7	_2embne _9183058 _aFarmacología _xInvestigación
700			_aWilliams III, Robert O. _eeditor literario _9101601
700	1		_aDavis Jr., Daniel A. _eeditor literario
700			_aMiller, Dave A. _eeditor literario _9101603
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9783030887186
776	0	8	_iPrinted edition: _z9783030887209
776	0	8	_iPrinted edition: _z9783030887216
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-88719-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eb _zSI